Africa’s leading drug manufacturer Aspen Pharmacare Holdings has reportedly agreed to acquire a unit of competitor Mereck & Co in a deal worth about $1 billion. In a statement, Aspen CEO Stephen Saad said the acquisition will aid his company’s output in Latin America and Asia, where the firm looks to strength its roots. According to reports, the agreement involves the buyout of a products unit, which uses molecules for therapeutic treatment including hormone replacement therapy and oral contraceptives. Aspen’s drugs unit is based in the Netherlands. The deal is the largest divestment made by Mereck since 2009.
Featured News
US Appeals Court Reinstates AI Pricing Antitrust Case Against Atlantic City Casinos
Jul 29, 2026 by
CPI
Democratic Senators Seek SEC Investigation Into Trump Media’s Premium
Jul 29, 2026 by
CPI
Publicis Challenges Naming in India Antitrust Investigation Before Delhi Court
Jul 29, 2026 by
CPI
Appeals Court Revives AI Hotel Pricing Antitrust Lawsuit Against Caesars, MGM
Jul 29, 2026 by
CPI
EU Warns FIFA Commercial Overhaul Could Violate Competition Law
Jul 29, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes